These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6673973)

  • 1. Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.
    St-Onge JM; Sirois G; Gagnon MA
    Eur J Drug Metab Pharmacokinet; 1983; 8(4):363-72. PubMed ID: 6673973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition kinetics of dihydroquinidine following quinidine administration.
    Ueda CT; Williamson BJ; Dzindzio BS
    Res Commun Chem Pathol Pharmacol; 1976 Jun; 14(2):215-25. PubMed ID: 940955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and electrocardiographic changes after oral 3-OH-quinidine in healthy subjects.
    Vozeh S; Uematsu T; Guentert TW; Ha HR; Follath F
    Clin Pharmacol Ther; 1985 May; 37(5):575-81. PubMed ID: 3987181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition kinetics of quinidine.
    Ueda CT; Hirschfeld DS; Scheinman MM; Rowland M; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Jan; 19(1):30-6. PubMed ID: 1245091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet.
    Martinez MN; Pelsor FR; Shah VP; Skelly JP; Honigberg IL; Hemingway SM; Gallo JM; Kotzan JA; Zaman R; Brown WJ
    Biopharm Drug Dispos; 1990; 11(1):17-29. PubMed ID: 2322634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bioavailability and kinetics of dihydroquinidine in patients with heart disease.
    Regazzi Bonora M; Salerno JA; Rondanelli R; Cristiani D; Chimienti M
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):212-8. PubMed ID: 7095920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics and dynamics of quinidine-N-oxide in healthy subjects.
    Ha HR; Vozeh S; Uematsu T; Guentert TW; Follath F
    Clin Pharmacol Ther; 1987 Sep; 42(3):341-5. PubMed ID: 3621790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients.
    Edwards DJ; Axelson JE; Visco JP; vanEvery S; Slaughter RL; Lalka D
    Br J Clin Pharmacol; 1987 Mar; 23(3):351-4. PubMed ID: 3567051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.
    Russo J; Russo ME; Smith RA; Pershing LK
    J Clin Pharmacol; 1982; 22(5-6):264-70. PubMed ID: 7107973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of quinidine.
    Ochs HR; Greenblatt DJ; Woo E
    Clin Pharmacokinet; 1980; 5(2):150-68. PubMed ID: 6988137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of quinidine in congestive heart failure.
    Ueda CT; Dzindzio BS
    Br J Clin Pharmacol; 1981 Jun; 11(6):571-7. PubMed ID: 7272173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
    Covinsky JO; Russo J; Kelly KL; Cashman J; Amick EN; Mason WD
    J Clin Pharmacol; 1979; 19(5-6):261-9. PubMed ID: 469022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absolute quinidine bioavailability.
    Ueda CT; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Sep; 20(3):260-5. PubMed ID: 954347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product.
    Meyer MC; Straughn AB; Lieberman P; Jacob J
    J Clin Pharmacol; 1982; 22(2-3):131-4. PubMed ID: 7068936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.
    Bottorff MB; Lalonde RL; Straughn AB
    Biopharm Drug Dispos; 1987; 8(3):213-21. PubMed ID: 3297181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.